| Name | Title | Contact Details |
|---|
Direct Action Medical Network is a Alexandria, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Intelligent Hospital Systems (IH Systems) is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kryosphere is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Catalyst OrthoScience, our goal is to develop innovative medical solutions that make orthopedic surgery less invasive and more efficient for both surgeons and patients. Catalyst OrthoScience was founded by a board-certified orthopedic surgeon and is comprised of a team of biomedical industry professionals with more than 100 years of combined medical device experience. The Catalyst CSR Total Shoulder System is the result of the visionary insight of Steven Goldberg, M.D., a fellowship-trained orthopedic surgeon and shoulder specialist, who devised the next generation, higher precision, less-invasive total shoulder solution with a greatly simplified method of implant placement. The key design elements of this new system are 1) to preserve as much of the patient`s bone as possible, 2) to create implants to better mimic the natural elliptical shape of the human shoulder, and 3) to provide a system that greatly improves the consistency and reproducibility of the operation.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.